FTC Escalates Battle With Teva Pharmaceuticals Over Inhaler Patents In Court

The fight between the Federal Trade Commission (FTC) and Teva Pharmaceutical over the drug maker’s Orange Book patent listings on inhaler products have reached a new level with FTC now going to court to back a press by Teva’s rival generic drug maker to get Teva to remove its patents from the Orange Book. Senate health committee Chair Bernie Sanders (I-VT) says there are indications Teva plans to lower its inhaler prices, but legal experts say that would sidestep the...